TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 374428
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of acetaminophen and propoxyphene
Study: 30557562
Drug: Baloxavir marboxil
Normalized name: Baloxavir Marboxil
DrugBank: Baloxavir marboxil (DB13997)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Baloxavir marboxil (40 mg for patients weighing <80 kg and 80 mg for patients weighing ≥80 kg)
Study: 28592311
Drug: Green cardamom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green cardamom (500 mg capsules, three times/day for 3 months)
Study: 28592311
Drug: Placebo (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500 mg capsules, three times/day for 3 months)
Study: 24502675
Drug: Zirconia implants
Normalized name: zirconium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zirconia implants (Ziterion vario Z(®))
Study: 24502675
Drug: Titanium implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titanium implants (Ziterion vario T(®))
Study: 19264155
Drug: Minodronate 1
Normalized name: Minodronate
DrugBank: Minodronic acid (DB06548)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Minodronate 1 mg once a day for 12 months
Study: 19264155
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg once a day for 12 months
Study: 16317313
Drug: ziprasidone 80‐160
Approvals — FDA: no, EMA: no, PMDA: no
Description: ziprasidone 80‐160 mg/day
Study: 16317313
Drug: chlorpromazine 200‐1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: chlorpromazine 200‐1200 mg/day
Study: 8329360
Drug: Lactose-enriched products
Normalized name: lactose Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose-enriched products (600 g/d)
Study: 8329360
Drug: Mg-enriched products
Normalized name: Pyelocalyceal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-enriched products (with added Mg)
Study: 3525068
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment with AVCF (Adriamycin, vincristine, cyclophosphamide, and 5-fluorouracil)
Study: 25758628
Drug: 100 μg carbetocin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg carbetocin shot
Study: 25758628
Drug: 20 IU oxytocin
Normalized name: oxytocin 20 UNT/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 IU oxytocin infusion
Study: 22616615
Drug: Anastrozole and
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole and fulvestrant in combination with gefitinib
Study: 19023831
Drug: Gain framed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gain framed messages with open label sustained-release (SR) bupropion
Study: 19023831
Drug: Loss framed
Normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Loss framed messages with open label sustained-release (SR) bupropion
Study: 16841678
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SI) low dose (0.3 ml/kg)
Study: 16841678
Drug: Shenfu Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenfu Injection (SI) high dose (0.6 ml/kg)
Study: 12636878
Drug: Once-per-cycle pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once-per-cycle pegfilgrastim 6 mg
Study: 12636878
Drug: Daily filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily filgrastim 5 microg/kg
Study: 12636878
Drug: Both pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Both pegfilgrastim and daily filgrastim
Study: 10812192
Drug: Cisplatin 100
Normalized name: CISPLATIN 100MG/VIL (PF) INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin 100 mg/m² iv day 1, Vinorelbine 25 mg/m² iv days 1-8-15-22, Amifostine 740 mg/m² iv day 1 every 4 weeks up to six cycles
Study: 1644464
Drug: Time of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time of starting treatment
Study: 6509461
Drug: Indapamide (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5, 5, or 10 mg once daily)
Study: 6509461
Drug: Hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrochlorothiazide (100 mg once daily)
Study: 30525950
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis 420™ (B420), 1010 cfu/d in 12 g microcrystalline cellulose
Study: 30525950
Drug: Litesse® Ultra™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litesse® Ultra™ polydextrose (LU), 12 g/day
Study: 30525950
Drug: Litesse® Ultra™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Litesse® Ultra™ polydextrose (LU) + B420, 1010 cfu/d of B420 in 12 g/d LU
Study: 30525950
Drug: Placebo, 12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 12 g/d microcrystalline cellulose
Study: 28834534
Drug: Electropalatography (EPG)
Normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electropalatography (EPG) therapy delivered in twice-weekly 30-minute sessions for 8 weeks
Study: 28834534
Drug: Electropalatography (EPG)
Normalized name: dyphylline / ephedrine hydrochloride / guaifenesin / phenobarbital Oral Solution [Lufyllin-EPG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electropalatography (EPG) therapy
Study: 21959071
Drug: Titrated oral
Normalized name: magnesium citrate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Titrated oral misoprostol (20 mL of misoprostol solution 1 μg/mL orally every 1 hour for 4 doses then titrated to 40 μg every 1 hour)
Study: 21959071
Drug: Conventional oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional oral misoprostol (50 μg of misoprostol orally every 4 hours up to 12 hours)
Study: 19673652
Drug: Egg-based trivalent
Normalized name: EGG
DrugBank: Egg (DB10529)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg-based trivalent inactivated influenza vaccine (TIV)
Study: 15522554
Drug: 5-year tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-year tamoxifen administration
Study: 15522554
Drug: 2-year tamoxifen
Normalized name: tamoxifen 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-year tamoxifen administration
Study: 11163295
Drug: Sinemet (25/250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet (25/250 mg)
Study: 9692700
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg b.d.; n = 10)
Study: 9692700
Drug: Lansoprazole (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole (30 mg b.d.; n = 10)
Study: 9692700
Drug: Pantoprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole (40 mg b.d.; n = 10)
Study: 7826791
Drug: Pethidine 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine 0.75 mg kg‐1 and clonidine 75 micrograms intrathecally
Study: 7826791
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% with morphine 0.5 mg
Study: 7864704
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg single dose
Study: 3293526
Drug: Ciprofloxacin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 1,000 mg (500 mg doses given 12 h apart)
Study: 31530046
Drug: In-hospital physiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital physiotherapy treatment (early mobilization, ambulation, breathing exercises, thoracic range of motion exercises)
Study: 31530046
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not receiving in-hospital physiotherapy treatment)
Study: 23727830
Drug: Pre-test measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-test measurement of sequential effect before manipulation phase
Study: 23727830
Drug: Post-test measurement
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-test measurement of sequential effect after manipulation phase with increased mechanical costs
Study: 16303817
Drug: Pulsed low-intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed low-intensity ultrasound therapy (LIUS)
Study: 15973019
Drug: Mycobacterium tuberculosis
Normalized name: MYCOBACTERIUM TUBERCULOSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium tuberculosis H37Ra excretory‐secretory antigen (ES‐31) and affinity purified goat anti ES‐31 antibodies
Study: 18796184
Drug: Naltrexone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (all doses)
Study: 18796184
Drug: Naltrexone (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (25 mg and 50 mg)
Study: 16953990
Drug: Twice-daily oral
Normalized name: Ferriprox 1000 MG Twice-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-daily oral hygiene care with 0.12% chlorhexidine gluconate
Study: 16953990
Drug: Standard oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oral care 6 times per day with soft foam swab and half strength hydrogen peroxide
Study: 15206694
Drug: Intermittent cyclosporin
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent cyclosporin A therapy
Study: 11316172
Drug: Prazosin 2
Normalized name: prazosin 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin 2 mg + Terlipressin 2 mg
Study: 11989841
Drug: Terlipressin 2
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin 2 mg
Study: 9643160
Drug: Lacidipine 4
Normalized name: lacidipine 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 4 mg
Study: 9643160
Drug: Lacidipine 6
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 6 mg
Study: 7609516
Drug: Lacidipine 8
Normalized name: LACIDIPINE
DrugBank: Lacidipine (DB09236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine 8 mg
Study: 7609516
Drug: Lacidipine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacidipine (all doses)
Study: 3129313
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) pulsatile LH‐RH therapy (50 to 100 ng/kg body weight/90 to 120 minutes)
Study: 3129313
Drug: Naloxone administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone administration (2 mg IV bolus plus 4 mg infusion lasting 120 minutes)
Study: 23948835
Drug: Deep cross-friction
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep cross-friction treatment on the thoraco-lumbar Erector spinae and gluteals, 30 minutes, two sessions per week
Study: 20980977
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (0.58 g/kg per day)
Study: 20980977
Drug: Usual protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual protein intake (1.3 g/kg per day)
Study: 20980977
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low protein intake (0.28 g/kg per day)
Study: 20980977
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein intake (0.58 g/kg per day) in study B
Study: 12895183
Drug: Vehicle applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle applied twice daily for 28 days
Study: 12895183
Drug: Ciclopirox gel
Normalized name: Ciclopirox
DrugBank: Ciclopirox (DB01188)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciclopirox gel 0.77%
Study: 10618300
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment (n=35)
Study: 3910771
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg twice daily (group CD)
Study: 3910771
Drug: Previous regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous regimen (beta-blockers and diuretics) (group BD)
Study: 26656672
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation treatment (four 30-min behavioral counseling sessions)
Study: 11834133
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of tibolone, taken daily for 12 months
Study: 11834133
Drug: Placebo pills,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pills, taken daily for 12 months
Study: 8510513
Drug: Intralipid 10%
Normalized name: Intralipid 10% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 10% (0.3 g triglyceride [TG]/kg/h for 6 hours)
Study: 8510513
Drug: Lipidem (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipidem (0.1 g/kg/h for 6 hours)
Study: 8510513
Drug: Both emulsions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both emulsions infused in random order (0.1 g/kg/h for 6 hours)
Study: 26659550
Drug: Lurasidone 20
Normalized name: lurasidone 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone 20 mg/day
Study: 23578605
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (10, 20, 40, or 80 μg/d)
Study: 23578605
Drug: ITCA 650
Approvals — FDA: no, EMA: no, PMDA: no
Description: ITCA 650 (40 and 80 μg/d)
Study: 21178082
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (400 mg/d from wk 20 of gestation through delivery)
Study: 12488300
Drug: Gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine alone (2,200 mg/m² biweekly)
Study: 12488300
Drug: Gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine plus capecitabine (2,200 mg/m² gemcitabine biweekly + 2,500 mg/m² capecitabine days 1-7)
Study: 9367703
Drug: Org 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 2766 (2 mg)
Study: 9367703
Drug: Org 2766
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Org 2766 (4 mg)
Study: 1552746
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX, 1 g/m2)
Study: 1552746
Drug: Successful remission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful remission retrieval therapy
Study: 27180101
Drug: Intramedullary implant
Normalized name: atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramedullary implant
Study: 26391465
Drug: Monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly dosing of intravitreal 0.5 mg ranibizumab
Study: 16627214
Drug: Antox (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antox (combined antioxidant preparation containing selenium, betacarotene, L-methionine, vitamins C and E)
Study: 11014092
Drug: 99mTc injection
Normalized name: 99mTc medronate
DrugBank: Technetium Tc-99m medronate (DB09138)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc injection (20‐40 MBq)
Study: 11014092
Drug: Blue dye
Normalized name: blue dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue dye injection
Study: 11014092
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 99mTc and blue dye
Study: 1464164
Drug: Rectal MST
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal MST administration
Study: 1464164
Drug: Oral MST
Normalized name: MST 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral MST administration
Study: 1464164
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and Rectal MST administration
Study: 6389060
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose with 50 g protein
Study: 6389060
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g protein alone
Study: 2197851
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose alone
Study: 6389060
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose with 50 g protein (second meal)
Study: 6389060
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g glucose (second meal)
Study: 22144003
Drug: MENTHOL SPRAY
Normalized name: menthol Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: MENTHOL SPRAY
Study: 22144003
Drug: CONTROL SPRAY
Normalized name: Nix Lice Control Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONTROL SPRAY
Study: 22144003
Drug: CON (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON (no spray)
Study: 22144003
Drug: CON-SPRAY (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: CON-SPRAY (control spray)
Study: 20347088
Drug: 50-microg dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-microg dose of misoprostol intravaginally 3 hours before oxytocin infusion
Study: 29215519
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion alone
Study: 15218994
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 microg once daily for 42 days
Study: 10926790
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day I‐3‐C
Study: 10926790
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day I‐3‐C
Study: 8395713
Drug: LMWH CY
Normalized name: Cys
DrugBank: Cysteine (DB00151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LMWH CY 216 (n = 35), subcutaneous injection, 6 months
Study: 8395713
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (n = 40), no specific treatment
Study: 216045
Drug: Amitriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline treatment
Study: 28558452
Drug: Tailor-made notched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailor-made notched music therapy
Study: 19873910
Drug: Electroacupuncture therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture therapy (Guanyuan (CV 4), Taixi (KI 3), Sanyinjiao (SP 6))
Study: 19873910
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antagonist scheme for ovulation induction without electroacupuncture)
Study: 17032148
Drug: Risedronate (RIS)
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Risedronate (RIS) 30 mg daily by mouth for 60 days
Study: 15863410
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (300 ml daily)
Study: 12410197
Drug: Zinc-fortified ORS
Normalized name: zinc gluconate Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-fortified ORS (40 mg/L)
Study: 12410197
Drug: Zinc syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc syrup (15 mg for 6-11 months; 30 mg for 12-35 months)
Study: 28747281
Drug: Transcutaneous electrical
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electrical nerve stimulation (1-hour sessions twice daily for 10 weeks)
Study: 28747281
Drug: Sham transcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transcutaneous electrical nerve stimulation (1-hour sessions twice daily for 10 weeks)
Study: 25526227
Drug: Once-daily, extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily, extended-release hydrocodone (Hysingla™ ER tablets)
Study: 21653932
Drug: Acyclovir 400
Normalized name: acyclovir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir 400 mg twice a day
Study: 7619676
Drug: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP)
Normalized name: L-glutamyl-L-tryptophan
DrugBank: Oglufanide (DB05779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-L-glutamyl-5-hydroxy-L-tryptophan (glu-5-HTP)
Study: 7826829
Drug: carbidopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: carbidopa (100 mg)
Study: 31449675
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intervention components
Study: 28662034
Drug: MA (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA (20 mg Sb+5/kg/day for 20 days)
Study: 28662034
Drug: LAMB (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMB (3 mg/kg/day for 7 days)
Study: 28662034
Drug: LAMB plus
Normalized name: Lamb
DrugBank: Lamb (DB10537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAMB plus MA (10 mg/kg single dose plus 20 mg Sb+5/kg/day for 10 days)
Study: 28662034
Drug: AmphoB (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AmphoB (1 mg/kg/day for 14 days)
Study: 20514956
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and morphine (group M)
Study: 20514956
Drug: Ondansetron and
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron and morphine (group O)
Study: 20514956
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (group C)
Study: 18541571
Drug: Selenium supplements
Normalized name: Selenium supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium supplements (200 mug as selenomethionine)
Study: 12482332
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including irinotecan, oxaliplatin, and 5-fluorouracil (5-FU) with leucovorin
Study: 7728786
Drug: Oral milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral milrinone 2.5 mg
Study: 7728786
Drug: Oral milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral milrinone 5 mg
Study: 7728786
Drug: Oral milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral milrinone 10 mg